KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Net Cash Flow (2016 - 2025)

Neogenomics' Net Cash Flow history spans 16 years, with the latest figure at -$4.5 million for Q4 2025.

  • For Q4 2025, Net Cash Flow fell 190.26% year-over-year to -$4.5 million; the TTM value through Dec 2025 reached -$207.4 million, down 945.68%, while the annual FY2025 figure was -$207.4 million, 945.68% down from the prior year.
  • Net Cash Flow reached -$4.5 million in Q4 2025 per NEO's latest filing, down from $9.4 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $372.5 million in Q1 2021 to a low of -$250.2 million in Q2 2021.
  • Average Net Cash Flow over 5 years is -$4.6 million, with a median of -$3.7 million recorded in 2022.
  • Peak YoY movement for Net Cash Flow: surged 1330.45% in 2023, then crashed 926.11% in 2025.
  • A 5-year view of Net Cash Flow shows it stood at -$26.9 million in 2021, then skyrocketed by 89.05% to -$2.9 million in 2022, then soared by 1330.45% to $36.2 million in 2023, then tumbled by 86.15% to $5.0 million in 2024, then tumbled by 190.26% to -$4.5 million in 2025.
  • Per Business Quant, the three most recent readings for NEO's Net Cash Flow are -$4.5 million (Q4 2025), $9.4 million (Q3 2025), and -$191.4 million (Q2 2025).